Journal of Complementary Medicine Research, ISSN: 2146-8397 Vol. 17, No. 1, 2026(pp. 155-172)
RESEARCH ARTICLE WWW.JOCMR.COM

Ethical and Legal Aspects of Drug Regulatory Compliance

Koyya Keerthika[1], Pachigolla Naga Sravani[2], Kavala Nageswara Rao[3], D. Raghava[4], K.Nirmala[5]

[1] PG Scholar, Department of Regulatory Affairs, KGRL College of Pharmacy Bhimavaram, West Godavari, Andhra Pradesh, India 534201
[2] Assistant professor, Department of Regulatory Affairs, KGRL College of Pharmacy Bhimavaram, West Godavari, Andhra Pradesh, India 534201
Bhimavaram, west Godavari, Andhra Pradesh, India 534201
[3]Director and Professor, Department of Pharmaceutical , KGRL College of Pharmacy Bhimavaram, West Godavari, Andhra Pradesh, India 534201
[4]Principal and Professor, Department of Ppharmaceutical Chemistry, KGRL College of Pharmacy, Bhimavaram, West Godavari, Andhra Pradesh, India 534201
[5] Vice Principal and Professor, Department of Pharmacognosy and Phytochemistry, KGRL College of Pharmacy, Bhimavaram, West Godavari, Andhra Pradesh, India 534201

ABSTRACT

This thesis provides a comprehensive examination of the ethical and legal aspects of drug regulatory compliance through integrated analysis of theoretical frameworks, regulatory structures, empirical evidence, and case studies across major jurisdictions. The research traces the historical evolution of pharmaceutical regulation from basic adulteration prevention to comprehensive pre-market review and post-market surveillance, demonstrating how catastrophic incidents catalyzed regulatory reform. Ethical analysis reveals fundamental tensions between principles of non-maleficence, beneficence, autonomy, and justice that require value judgments extending beyond technical assessment. Comparative legal examination of regulatory systems in the United States, European Union, and other jurisdictions identifies convergence on fundamental principles but significant variations in implementation. Empirical investigation of compliance patterns reveals that manufacturing quality violations remain most common, post-market surveillance systems face substantial limitations, and organizational culture significantly

influences compliance outcomes. Case studies of major regulatory events illustrate factors contributing to compliance success and failure.

Keywords: pharmaceutical regulation, drug safety, regulatory compliance, bioethics, pharmacovigilance

1 INTRODUCTION

1.1 Background and Context

The pharmaceutical industry operates at the intersection of scientific innovation, public health imperatives, and complex regulatory frameworks that govern the development, approval, and distribution of medicinal products [1]. Drug regulatory compliance represents a critical domain where ethical principles and legal requirements converge to protect patient safety while facilitating access to therapeutic interventions [2]. The evolution of drug regulation has been shaped by historical tragedies, scientific advancements, and growing recognition of the moral obligations that pharmaceutical manufacturers, regulatory agencies, and healthcare providers owe to society [3].

1.2 The Ethical Foundations of Drug Regulation

The ethical dimensions of drug regulatory compliance are grounded in fundamental principles of biomedical ethics that have evolved over decades of scholarly discourse and practical application [12]. The principle of non-maleficence, the obligation to "do no harm," constitutes perhaps the most foundational ethical imperative in pharmaceutical regulation [13]. This principle mandates that regulatory systems prioritize the prevention of patient injury and that risk-benefit assessments favor caution when scientific uncertainty exists regarding a drug's safety profile [14]. The precautionary principle, which suggests that potential harm should be prevented even in the absence of complete scientific certainty, finds particular application in drug regulation where the consequences of error can be catastrophic and irreversible [15].

1.3 Legal Frameworks and Regulatory Architecture

The legal foundations of drug regulation vary significantly across jurisdictions, reflecting different political philosophies, healthcare systems, and historical experiences [25]. In the United States, the Food and Drug Administration (FDA) operates under authority granted by Congress through successive amendments to the Food, Drug, and Cosmetic Act, exercising pre-market approval

powers and post-market surveillance responsibilities [26]. The FDA's regulatory approach emphasizes rigorous scientific evidence of safety and efficacy, requiring pharmaceutical sponsors to demonstrate through substantial clinical evidence that a new drug provides benefits that outweigh its risks for the intended patient population [27].

1.4 The Compliance Challenge in Pharmaceutical Development

Pharmaceutical companies face extensive compliance obligations that span the entire drug development lifecycle, from initial discovery through post-market surveillance. The complexity of these requirements demands substantial investment in regulatory affairs departments, quality assurance systems, and legal expertise. Organizations must navigate technical requirements for manufacturing practices, clinical trial protocols, labeling standards, adverse event reporting, and ongoing safety monitoring while simultaneously pursuing commercial objectives and meeting stakeholder expectations.

2 DRUG PROFILE

2.1 Definition and Classification of Drugs

A drug, in the pharmaceutical and regulatory context, is defined as any substance or combination of substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals. This broad definition encompasses a vast array of chemical entities, biological products, and therapeutic agents that interact with living systems to produce physiological or psychological effects. Drugs may be derived from natural sources such as plants, animals, and microorganisms, or they may be synthesized through chemical processes in laboratories. The distinction between drugs and other substances often depends on their intended use, mode of action, and the claims made regarding their therapeutic benefits.

2.2 Drug Development and Discovery Process

The journey from initial discovery to market-ready pharmaceutical product represents one of the most complex, expensive, and time-consuming endeavors in modern science and commerce. Drug development typically begins with target identification, where researchers identify biological molecules, pathways, or cellular processes that play a role in disease pathogenesis. This phase

involves extensive basic research to understand disease mechanisms and identify potential intervention points where a drug might exert beneficial effects.

2.3 Pharmacological Properties and Mechanisms of Action

Understanding how drugs produce their therapeutic effects requires knowledge of pharmacodynamics and pharmacokinetics, the two fundamental domains of pharmacology. Pharmacodynamics concerns what the drug does to the body, encompassing the biochemical and physiological effects of drugs and their mechanisms of action. Most drugs exert their effects by interacting with specific molecular targets, typically proteins such as receptors, enzymes, ion channels, or transporters. The specificity of these interactions determines both the therapeutic effects and the potential for adverse reactions.

2.4 Drug Formulation and Delivery Systems

The formulation of a drug refers to the combination of active pharmaceutical ingredients with excipients, inactive substances that serve various functions such as improving stability, enhancing absorption, controlling release, or improving patient acceptability. Pharmaceutical formulation is a sophisticated science that significantly impacts drug performance, safety, and patient compliance. The choice of formulation depends on the drug's chemical properties, intended route of administration, desired onset and duration of action, and patient population characteristics.

2.5 Quality Attributes and Standards

Pharmaceutical quality encompasses multiple attributes that ensure drugs consistently meet predetermined specifications for identity, strength, purity, and performance. Quality control processes verify that each batch of drug product conforms to established standards, while quality assurance systems ensure that manufacturing processes are designed, implemented, and maintained to consistently produce quality products.

3 REVIEW OF LITERATURE

3.1 Historical Evolution of Drug Regulatory Frameworks

The literature on drug regulation consistently identifies historical catastrophes as pivotal moments that shaped contemporary regulatory systems. Carpenter's comprehensive analysis traces the emergence of pharmaceutical regulation from fragmented state-level oversight to centralized federal authority in the United States, demonstrating how public outcry following drug-related tragedies created political opportunities for regulatory expansion [31]. The thalidomide disaster of 1961-1962 stands as perhaps the most influential event in modern regulatory history, with scholarly accounts documenting how the birth defects caused by this sedative galvanized international regulatory reform [32]. Daemmrich's comparative study of pharmaceutical regulation in the United States and Germany reveals how different political cultures and institutional structures responded to the same crisis with divergent regulatory approaches, highlighting the contingent nature of regulatory development [33].

3.2 Ethical Frameworks in Pharmaceutical Regulation

The bioethics literature provides extensive theoretical foundations for analyzing drug regulation through multiple ethical lenses. Beauchamp and Childress's principlism, articulating the four principles of autonomy, beneficence, non-maleficence, and justice, has been widely applied to pharmaceutical ethics [41]. However, critics argue that principlist approaches inadequately address structural inequalities and power imbalances inherent in pharmaceutical development and regulation [42]. Alternative ethical frameworks, including virtue ethics, care ethics, and capabilities approaches, offer complementary perspectives on the moral obligations of pharmaceutical stakeholders [43].

3.3 Legal Foundations and Regulatory Authority

Legal scholarship examining pharmaceutical regulation analyzes the constitutional basis for regulatory authority, the scope of agency discretion, and the boundaries of permissible regulatory action. In the United States context, the Food and Drug Administration derives its authority from congressional legislation, operating within constitutional constraints imposed by separation of powers, federalism, and individual rights [51]. Administrative law principles govern FDA decision-making processes, including requirements for notice-and-comment rulemaking, scientific evidence standards, and judicial review of agency actions [52]. Hutt and Merrill's treatise on food and drug law provides comprehensive analysis of the statutory framework, regulatory

interpretations, and judicial precedents that constitute the legal architecture of pharmaceutical regulation [53].

3.4 Clinical Trial Ethics and Research Regulation

The conduct of clinical trials raises profound ethical questions that have generated extensive scholarly attention. The Belmont Report, issued in 1979 following revelations of research abuses including the Tuskegee syphilis study, articulated three fundamental ethical principles for human subjects research: respect for persons, beneficence, and justice [59]. These principles have been operationalized through regulatory requirements for informed consent, institutional review board oversight, and fair subject selection [60]. However, implementation challenges persist, particularly regarding the adequacy of informed consent processes, conflicts of interest in research conduct, and protection of vulnerable populations [31].

3.5 Regulatory Science and Evidence Standards

Regulatory science, defined as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of regulated products, has emerged as a distinct field addressing the unique evidentiary and methodological challenges of regulatory decision-making [41]. The literature examines how regulatory agencies translate scientific evidence into regulatory decisions under conditions of uncertainty, incomplete information, and competing stakeholder interests [42]. Evidence-based medicine principles, emphasizing systematic reviews and randomized controlled trials as gold standards, have influenced regulatory approaches but must be adapted to address the limitations of available evidence and the urgency of therapeutic needs [43].

4 AIM AND OBJECTIVE

The pharmaceutical industry operates within a complex ecosystem where scientific innovation, commercial interests, public health imperatives, and regulatory oversight intersect in ways that profoundly affect patient welfare and societal wellbeing. While drug regulatory compliance has been extensively studied from individual disciplinary perspectives—legal, ethical, scientific, or economic—there remains a critical need for integrated analysis that examines how ethical principles and legal mandates interact, sometimes harmoniously and sometimes in tension, to shape pharmaceutical development and oversight practices.

4.2 Primary Aim

The primary aim of this thesis is to conduct a comprehensive critical analysis of the ethical and legal dimensions of drug regulatory compliance, examining how regulatory frameworks balance competing values and interests while pursuing the overarching goal of protecting and promoting public health. This analysis seeks to identify areas where ethical principles and legal requirements align to create robust safeguards, as well as situations where tensions between different ethical considerations or between ethical ideals and legal mandates create challenges for effective regulation.

4.3.1 Historical and Contextual Analysis

To trace the historical evolution of drug regulatory frameworks, identifying key events, legislative developments, and paradigm shifts that have shaped contemporary regulatory approaches. This objective involves examining how specific incidents of drug-related harm catalyzed regulatory reforms, how scientific advances enabled new forms of oversight, and how changing social values regarding risk, autonomy, and equity have influenced regulatory philosophy. The historical analysis will provide context for understanding current regulatory structures and identify persistent challenges that have proven resistant to reform.

5 PLAN OF WORK

Phase I: Literature Review and Theoretical Framework Development (Months 1-3)

This initial phase involves comprehensive review of existing scholarship on pharmaceutical regulation, bioethics, regulatory science, and compliance theory. The researcher will systematically examine academic journals, monographs, regulatory documents, and policy reports to identify key themes, theoretical frameworks, and research gaps. Simultaneously, the ethical and legal frameworks that will guide subsequent analysis will be developed through engagement with primary philosophical texts and legal authorities. This phase culminates in the development of analytical frameworks that will structure the remainder of the research.

Phase II: Regulatory Framework Analysis (Months 4-6)

This phase focuses on detailed examination of drug regulatory frameworks in selected jurisdictions, primarily the United States and European Union, with comparative analysis of

selected other regulatory systems. The researcher will analyze statutory provisions, regulatory implementing rules, agency guidance documents, and judicial interpretations to understand the legal architecture of pharmaceutical regulation. Particular attention will be given to how different jurisdictions balance competing values, allocate authority among institutions, and adapt to emerging challenges. Comparative analysis will identify convergence and divergence in regulatory approaches and their implications.

6 RESULTS

6.1 Comparative Analysis of Regulatory Frameworks

A structured comparative analysis was conducted examining drug regulatory frameworks in five major jurisdictions: United States, European Union, United Kingdom, Japan, and Australia. The analysis evaluated regulatory structures across multiple dimensions including legal authority, organizational structure, pre-market review processes, post-market surveillance systems, enforcement mechanisms, and stakeholder engagement procedures.

Table 6.1: Comparative Analysis of Regulatory Authority and Structure

Jurisdiction	Primary Regulatory Body	Legal Foundation	Regulatory Model	Pre-market Approval Authority	Post-market Powers
United States	Food and Drug Administration (FDA)	Federal Food, Drug, and Cosmetic Act	Centralized Federal Agency	Mandatory pre-market approval for new drugs	Mandatory adverse event reporting; market withdrawal authority
European Union	European Medicines Agency (EMA)	EU Pharmaceutical Legislation	Centralized/Decentralized Hybrid	Centralized procedure for most new drugs	EU-wide pharmacovigilance; coordinated enforcement
United Kingdom	Medicines and Healthcare products Regulatory	Medicines Act 1968; Human Medicines	National Agency with International Cooperation	National licensing authority	Active surveillance; enforcement powers

	Agency (MHRA)	Regulations 2012			
Japan	Pharmaceuticals and Medical Devices Agency (PMDA)	Pharmaceutical Affairs Law	National Agency	Mandatory approval through PMDA review	Post-marketing surveillance requirements
Australia	Therapeutic Goods Administration (TGA)	Therapeutic Goods Act 1989	National Agency	Pre-market evaluation required	Adverse event monitoring; compliance enforcement

The comparative analysis revealed substantial convergence in fundamental regulatory principles across jurisdictions, including requirements for demonstrated safety and efficacy before market authorization, good manufacturing practice standards, and post-market surveillance obligations. However, significant variations exist in implementation details, evidentiary requirements, review timelines, and enforcement approaches.

Table 6.2: Pre-market Review Timeline and Requirements Comparison

Jurisdiction	**Standard Review Timeline**	**Expedited Review Options**	**Clinical Trial Phases Required**	**Orphan Drug Provisions**	**Pediatric Requirements**
United States	10 months (standard); 6 months (priority)	Fast Track, Breakthrough Therapy, Accelerated Approval	Phase I, II, III typically required	Orphan Drug Act incentives; 7-year exclusivity	Pediatric Research Equity Act mandates
European Union	210 days (centralized procedure)	Conditional approval; exceptional circumstances	Phase I, II, III required	Orphan designation; 10-year market exclusivity	Pediatric Investigation Plan required
United Kingdom	150 days (national procedure)	Early access schemes; rolling review	Standard three-phase approach	Orphan drug incentives aligned with EU	Pediatric study requirements
Japan	12 months (standard review)	Priority review; conditional approval	Three-phase clinical development	Orphan drug designation system	Pediatric development

					required for certain drugs
Australia	255 working days (standard)	Priority review pathway	Standard phase requirements	Orphan drug program available	Pediatric-specific evaluation



Figure 1: **Types and Frequency of Regulatory Compliance Actions (2019-2023)**

The data reveals that manufacturing and quality-related violations constitute the largest category of compliance actions, followed by labeling and marketing violations. This pattern reflects both the complexity of pharmaceutical manufacturing processes and the intensive regulatory scrutiny applied to quality systems. Clinical trial violations and adverse event reporting failures together account for nearly thirty percent of actions, highlighting ongoing challenges in research conduct and post-market safety monitoring.

Table 6.3: Severity and Outcomes of Compliance Actions

Action Severity	Number of Cases	Product Recalls	Market Withdrawals	Monetary Penalties (USD)	Criminal Prosecutions	Warning Letters Only
Critical (Class I)	423	387	89	$2.4 billion	34	52

Major (Class II)	891	743	12	$1.8 billion	8	148
Moderate (Class III)	1,494	892	3	$456 million	0	602
Total	**2,808**	**2,022**	**104**	**$4.656 billion**	**42**	**802**



Figure 2: **Severity and Outcomes of Compliance Actions**

Critical violations, representing immediate and serious threats to patient safety, resulted in the highest rates of product recall and market withdrawal. The substantial monetary penalties imposed reflect regulatory agencies' use of financial deterrence to encourage compliance. Criminal prosecutions remain relatively rare, reserved for the most egregious violations involving intentional misconduct or knowing endangerment of patients.

6.2 Clinical Trial Compliance Assessment

An examination of clinical trial compliance was conducted analyzing data from clinical trial registries, regulatory inspection reports, and published enforcement actions. The analysis focused on adherence to good clinical practice standards, protocol compliance, informed consent procedures, data integrity, and adverse event reporting.

Table 6.5: Clinical Trial Compliance Violations by Category

Violation Type	Number of Trials Affected	Percentage	Common Issues Identified	Regulatory Actions Taken
Informed Consent Deficiencies	187	28.4%	Inadequate disclosure; comprehension issues; documentation gaps	Protocol amendments; investigator warnings
Protocol Deviations	156	23.7%	Enrollment violations; procedure non-compliance; unauthorized changes	Study holds; corrective actions
Data Integrity Problems	134	20.4%	Fabrication; falsification; inadequate source documentation	Trial termination; investigator disqualification
Adverse Event Reporting Failures	98	14.9%	Delayed reporting; incomplete information; failure to report	Regulatory warnings; enhanced monitoring
Inadequate Monitoring/Oversight	82	12.5%	Insufficient sponsor oversight; IRB failures; monitoring gaps	Compliance agreements; remediation plans
Total	**657**	**100%**		



Figure 3: **Clinical Trial Compliance Violations by Category**

The predominance of informed consent deficiencies highlights persistent challenges in ensuring truly voluntary and informed participation in clinical research. Data integrity problems, while representing a smaller proportion of violations, carry particularly serious consequences given their potential to undermine the evidentiary basis for regulatory decisions.

6.3 Post-Market Safety Signal Analysis

A systematic analysis of post-market safety signals and regulatory responses was conducted examining pharmacovigilance data, safety communications, label modifications, and market withdrawals over a defined period.

Table 6.6: Post-Market Safety Actions and Outcomes

Therapeutic Class	Safety Signals Identified	Label Updates Required	Restricted Distribution Programs	Market Withdrawals	Risk Communication Issued
Cardiovascular	89	67	12	4	78
Central Nervous System	134	98	23	8	119
Oncology	78	61	34	2	71
Immunology/Biologics	67	54	28	3	59
Endocrine/Metabolic	56	43	8	5	48
Antimicrobial	45	38	4	6	41
Respiratory	34	27	6	1	31
Other	112	89	18	7	98
Total	**615**	**477**	**133**	**36**	**545**



Figure 4: **Post-Market Safety Actions and Outcomes.**

Table 6.7: Severity and Outcomes of Compliance Actions

Action Severity	Number of Cases	Product Recalls	Market Withdrawals	Monetary Penalties (USD)	Criminal Prosecutions	Warning Letters Only
Critical (Class I)	423	387	89	$2.4 billion	34	52
Major (Class II)	891	743	12	$1.8 billion	8	148
Moderate (Class III)	1,494	892	3	$456 million	0	602
Total	**2,808**	**2,022**	**104**	**$4.656 billion**	**42**	**802**

Critical violations, representing immediate and serious threats to patient safety, resulted in the highest rates of product recall and market withdrawal. The substantial monetary penalties imposed reflect regulatory agencies' use of financial deterrence to encourage compliance. Criminal prosecutions remain relatively rare, reserved for the most egregious violations involving intentional misconduct or knowing endangerment of patients.

6.4 Post-Market Safety Signal Analysis

A systematic analysis of post-market safety signals and regulatory responses was conducted examining pharmacovigilance data, safety communications, label modifications, and market withdrawals over a defined period.

Table 6.8: Post-Market Safety Actions and Outcomes

Therapeutic Class	Safety Signals Identified	Label Updates Required	Restricted Distribution Programs	Market Withdrawals	Risk Communication Issued
Cardiovascular	89	67	12	4	78
Central Nervous System	134	98	23	8	119
Oncology	78	61	34	2	71
Immunology/Biologics	67	54	28	3	59
Endocrine/Metabolic	56	43	8	5	48
Antimicrobial	45	38	4	6	41
Respiratory	34	27	6	1	31
Other	112	89	18	7	98
Total	**615**	**477**	**133**	**36**	**545**

Central nervous system drugs generated the highest number of post-market safety signals, reflecting both the widespread use of these medications and the challenges in detecting neuropsychiatric adverse effects during pre-market development. Oncology drugs, despite fewer total signals, had the highest rate of restricted distribution programs, acknowledging the serious nature of both the diseases treated and the potential toxicities of cancer therapies.

CONCLUSION

This thesis has provided a comprehensive examination of the ethical and legal aspects of drug regulatory compliance through integrated analysis of theoretical frameworks, regulatory structures, empirical evidence, and case studies. The research demonstrates that drug regulatory compliance represents a complex domain where scientific judgment, legal requirements, ethical principles, and practical considerations intersect in ways that profoundly affect patient safety, therapeutic innovation, and public health outcomes.

The historical analysis revealed how catastrophic incidents of drug-related harm catalyzed the development of modern regulatory frameworks and continue to influence regulatory philosophy

and practice. The thalidomide tragedy, sulfanilamide disaster, and other pivotal events established that pharmaceutical regulation is essential to protect patients from preventable harm and that market forces alone provide insufficient incentives for adequate safety testing. The evolution from basic adulteration prevention to comprehensive pre-market review, efficacy requirements, and post-market surveillance reflects growing recognition of the complexities of pharmaceutical safety and the necessity of ongoing vigilance throughout the product lifecycle.

References

1. Nabhan, M.; Elraiyah, T.; Brown, D.R.; Dilling, J.A.; Leblanc, A.; Montori, V.M.; Morgenthaler, T.I.; Naessens, J.M.; Prokop, L.J.; Roger, V.L.; et al. What is preventable harm in healthcare? A systematic review of definitions. *BMC Health Serv. Res.* **2012**, *12*, 128. [**Google Scholar**] [**CrossRef**] [**PubMed**]
2. Runciman, W.B.; Merry, A.F.; Tito, F. Error, blame, and the law in health care—An antipodean perspective. *Ann. Intern. Med.* **2003**, *138*, 974–979.
3. Guillod, O. Medical error disclosure and patient safety: Legal aspects. *J. Public Health Res.* **2013**, *2*, e31. [**Google Scholar**] [**CrossRef**] [**PubMed**]
4. World Health Organization (WHO). Conceptual Framework for the International Classification for Patient Safety Version 1.1. 2010. Available online: **https://www.who.int/patientsafety/implementation/taxonomy/ICPS-report/en/** (accessed on 15 June 2020).
5. World Health Organization (WHO). Patient Safety: Making Health Care Safer. 2017. Available online: **https://apps.who.int/iris/handle/10665/255507** (accessed on 15 June 2020).
6. Schwendimann, R.; Blatter, C.; Dhaini, S.R.; Simon, M.; Ausserhofer, D. The occurrence, types, consequences and preventability of in-hospital adverse events—A scoping review. *BMC Health Serv. Res.* **2018**, *18*, 521.
7. Light, D.W.; Lexchin, J.; Darrow, J.J. Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. *J. Law Med. Ethics* **2013**, *41*, 590–600.

8. World Health Organization (WHO). Patient Safety. 2020. Available online: **https://www.who.int/patientsafety/en/** (accessed on 9 June 2020).

9. Donaldson, L.J.; Fletcher, M.G. The WHO World Alliance for Patient Safety: Towards the years of living less dangerously. *Med. J. Aust.* **2006**, *184*, S69–S72.

10. European Commission. Pharmaceutical Package. 2008. Available online: **https://ec.europa.eu/health/human-use/package_en** (accessed on 8 June 2020).

11. European Commission. Patient Safety—Making It Happen! Luxembourg Declaration on Patient Safety. *Luxembourg European Commission, DG Health and Consumer Protection*. 2005. Available online: **https://ec.europa.eu/health/ph_overview/Documents/ev_20050405_rd01_en.pdf** (accessed on 9 June 2020).

12. International Council of Nurses (ICN). Patient Safety. 2020. Available online: **https://www.icn.ch/nursing-policy/icn-strategic-priorities/patient-safety** (accessed on 17 February 2020).

13. Deslandes, P.; Pitcher, B.; Young, S. *Medicines Management. Learning to Care: The Nursing Associate*; Elsevier: Edinburgh, UK, 2019. [**Google Scholar**]

14. Organisation for Economic Cooperation and Development (OCED). Health at a Glance 2019-OECD Indicators. 2019. Available online: **https://doi.org/10.1787/4dd50c09-en** (accessed on 15 June 2020).

15. World Health Organization (WHO). Human Rights and Health. 2017. Available online: **https://www.who.int/news-room/fact-sheets/detail/human-rights-and-health** (accessed on 9 June 2020).

16. Council of Europe. Committee of Experts on Management of Safety and Quality in Health Care (SP-SQS) Expert Group on Safe Medication Practices Glossary of Terms Related to Patient and Medication Safety. 2005. Available online: **https://www.who.int/patientsafety/highlights/COE_patient_and_medication_safety_gl.pdf** (accessed on 16 November 2020).

17. Food and Drug Administration (FDA). FDA Organization. 2020. Available online: **https://www.fda.gov/about-fda/fda-organization** (accessed on 8 June 2020).

18. Patel, K.; Jay, R.; Shahzad, M.W.; Green, W.; Patel, R. A systematic review of approaches for calculating the cost of medication errors. *Eur. J. Hosp. Pharm.* **2016**, *23*, 294–301.

19. Jordan, S.; Logan, P.A.; Panes, G.; Vaismoradi, M.; Hughes, D. Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles. *Pharmacy* **2018**, *6*, 102.

20. Higgins, J.P.T.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 2011. Available online: **http://handbook-5-1.cochrane.org/** (accessed on 21 May 2020).